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Abstract: Disputes take place among many scientists about the position of MC in the classification of breast cancer. Some 
say that this kind of tumor is a sign of invasive ductal carcinoma (IDC). Instead, most of modern researchers distinguish 
MC of the breast as a separate nosological unit.
Primarily there were selected 20 cases of MC and 10 cases of IDC (as control group). The immunohistochemical study 
revealed the presence of ER, PR, HER2/neo, p53, Ki-67, MMP1 and E-cadherin receptors.
In the study of receptor status of tumors it was observed that 100% of MC cases were estrogen-, progesterone- and HER2/
neu negative. The status of tumors on receptor p53 and Ki-67 was as follows: p53+ status had 80% and Ki-67+ had 85% of 
tissues of MC. In 75% of cases MC cells expressed marker of adhesion and in 100% of cases cells were receptor-negative 
for expression of MMP1.
The data of the study show that the invasive ductal carcinoma and medullary carcinoma are completely independent and 
different types of malignancy in the breast. The favorable behavior of medullary cancer is associated with expression of 
E-cadherin receptors, which are essentially adhesion factor and absence of MMP1 which are factors of metastatic poten-
tial of the tumor. 
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Introduction
There are more than 50 histological types of breast cancer (BC). According to research data 
the medullary carcinoma (MC) estimates from 1% to 7% among them and sometimes is up 
to 10% [1]. The average age of patients ranges from 45 to 54 years old [2]. Women younger 
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than 35 years old make up 10%. The MC cases more often occur with Japanese and Afri-
can-Americans women compared to women of the white race. Bilateral damages are observed 
in 3–18%, the multicentric character of growth in one breast is indicated in 10% of cases 
[3]. It should be noted that neither of studied groups has reported about the MC case in 
men [4].
Disputes take place among many scientists about the position of MC in the classification 
of breast cancer. Some say that this kind of tumor is a sign of invasive ductal carcinoma 
(IDC) [5]. Instead, most of modern researchers distinguish MC of the breast as a separate 
nosological unit. Discrepancy of highly malignant morphological picture and relatively 
favorable behavior of the tumor distinguishes it from the total number of infiltrating carci-
nomas. Having morphological features of a low differentiated tumor with marked nuclear 
and cellular atypia and a high level of proliferation, MC, in most cases, had to be classified 
to the third degree of malignancy according to Scarff-Bloom-Richardson system, but the 
biological behavior of the tumor, however, is less aggressive [6].
The immunohistochemical investigations allow defining more precisely the type of 
breast cancer, to prescribe purposeful treatment and to predict the course of illness in each 
determined case by the identification of receptors in breast tumor tissue. The presence of 
estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor 
receptor 2 (HER2/neo) determines the prognosis and sensitivity of tumor to antihormonal 
and monoclonal therapy; it also correlates with the histological differentiation of the tumor. 
The degree of receptors expression for steroid hormones is inversely proportional to the 
degree of aneuploidy of cancer cells [7].
The presence of factors that regulate programmed cell death (proapoptotic marker p53) 
and the proliferative activity (marker Ki-67) determines the prognosis of BC [8]. The accu-
mulation of p53 indicates the aggressive behavior of the tumor, a shorter disease-free and 
non-metastasis period, worse prognosis and the necessity of more aggressive therapy. The 
study of non-histone protein Ki-67 allows to determine “hidden” proliferative potential of 
the tumor and to assess the degree of malignancy, to divide patients into groups with rela-
tively favorable and unfavorable prognosis [9]. 
Metastatic readiness of tumor cells is determined by the presence of E-cadherin receptors 
and matrix metalloproteinase 1 (MMP1). E-cadherin is a membrane protein, which partici-
pates in homophylic interactions, forming intercellular contacts [10]. It is involved into the 
regulatory mechanisms of intercellular adhesion, cell motility and proliferation of epithelial 
cells, plays a potential antagonistic role in the ability of cells to invasion [11]. MMR1 is the 
collagenase. Hydrolyzing collagen of vascular walls and the surrounding matrix environment, 
they allow tumor’s cells to spread and to metastasize [12].
According to various sources the lack of ER and PR expression is typical for MC tumor 
cells, while in some works there were not found any difference in the levels of the expression 
of ER and PR in comparison with IDC [13]. The percentage of HER2/neo expression in MC 
is ranged from 10% to 33%, while other investigations have found that all MC tumors had 
been HER2/neo negative. The frequency of monitoring of p53 in MC tumors is different 
too. Some scientists argue that p53 is found in 100% of cases of MC, others see no difference 
compared with IDC [14].
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At present, there are no simple and clear morphological criteria that would allow eliminate 
the risk of over- and underdiagnosis of typical medullary cancer. Thus, the objectives of this 
paper are as follows: to establish peculiarities of medullary breast cancer course, comparing 
it with invasive ductal cancer, taking into account the expression of ER, PR, HER2/neu, p53, 
Ki-67, E-cadherin and MMR1 by tumor cells.
Material and methods
Primarily there were selected 20 cases of MC and 10 cases of IDC (as control group). The 
criteria of MP selection were 5 signs according to the recommendation of World Health 
Organization Classification of Tumours of the breast: syncytial structure of tumors, the 
absence of tubular and glandular structures, lymphoplasmacytic infiltration, high-grade 
polymorphism and histological circumscription or pushing margin.
The material for the immunohistochemical study was fixed in 10% neutral formalin for 
24 hours, and then paraffin blocks were made of it. Then sections with the thickness of 
3–4 mm were made and they were subjected to the standard process of dehydration in xylene 
and alcohols of rising concentration. The monoclonal antibodies (firm «Dako») in different 
dilutions were used for determination the expression of receptors:
— the antibodies for ER (clone SR1) and PR (clone SR2) with assessment of their expres-
sion according to DC Allred recommendations (taking into account the proportion of 
stained nuclei and the intensity of their staining) [15] were used for identifying receptors 
to steroid hormones;
— the antibodies for HER2/neo (clone SR3) were used to determine the expression of epi-
dermal growth factor receptors. We performed evaluation of reactions using the point 
scale — 0, 1+, 2+, 3+, which were developed by the manufacturer and were approved by 
FDA [16];
— the cell’s proliferative activity was assessed taking into account the number of positively 
stained cells;
— p53 antibodies (clone SR5) were used for determination the pro-apoptotic receptor. 
Recommendations of the American research laboratory were used for determination 
p53-receptor status: a positive result was defined as distinct nuclear staining in at least 
10% of the carcinoma cells;
— E-cadherin antibodies (clone SPM471) were used for determination the adhesive re-
ceptors and MMR1 polyclonal antibodies were used for determination the collagenase 
activity of tumor. The results were evaluated by semiquantitative method: 0 points — no 
reaction, 1 point — poor response, 2 points — moderate reaction, 3 points — severe 
reaction.
Mathematical calculations were done using Microsoft Excel 2010 with 12.0.5 Attestat 
option. We found such indicators as chi-squared Pearson’s test, Student’s T-criterion (with 
statistical significance p <0.05).
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Research results
Breast cancer in Sumy, as in Ukraine and in most countries of the world, progresses and 
nowadays occupies the first place in the structure of women morbidity (26–28% of all can-
cers). Among all types of breast cancer, MC accounts for about 4%.
Macroscopically it is presented by clearly defined, moderately dense tumor foci of round 
form. The foci is 2–3 cm in diameter, less dense than other forms of cancers (tumors of soft 
consistency, similar to brain tissue), has signs of fibrosis in the peripheral zone, which can 
simulate the capsule. Sometimes the tumor boundaries are unclear, due to the presence of 
lymphoid infiltration. The surface of the cut is smooth, sometimes slightly convex, juicy, 
matte, with gray color, small hemorrhages and foci of necrosis. Histological examination 
of the tumor is characterized by syncytial growth (more than 75% of the cut), the absence 
of glands and tubes (even in small amounts), with expressed lymphoplasmacytic infiltration 
of the stroma (Fig. 1), moderate or severe cellular polymorphism, which corresponds to 
a moderate or low level of histological differentiation (G2 or G3). The edges of the tumor 
can be compressed by peripheral fibrous tissue in the form of pseudo capsule.
Fig. 1. Histologic picture of MC (A) and IDС (B) of mammary gland; 1 — tumor cells, 2 — lymphocytic 
infiltration. Staining with hematoxylin-eosin. Increase × 300.
IDС of mammary gland is macroscopically characterized by tumor foci, which can be 
divided into two groups: stellate (infiltrative) or clearly defined (round) shape. Consistence 
is different, oftener more denser then for MC. Due to infiltrative growth of the carcinoma 
the boundaries of the tumor are not clear. It has gray-yellow color with areas of secondary 
changes such as mucinization, calcification, hemorrhages and necrosis. In cases of high 
histological differentiation of tumor growth cancer cells form mainly glandular, tubular 
structures. With the decrease of cancer differentiation the volume of stroma decreases, the 
cancer cells form a solid field. Sometimes relatively isolated accumulations of tumor cells 
are dominated. In most cases the tumor tissue is composed of large cells, which have lost 
the opportunity to the typical distribution of epithelium in the form of layers, but retain 
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tends to adhesion. In the cells there is well visible cytoplasm and large polymorphic nucle-
us with several nucleoli. Pathological mitosis is expressed in the different stages with ugly 
multi-cells formation.
In the study of receptor status of tumors (Fig. 2) it was observed that 100% of MC cases 
were estrogen-, progesterone- and HER2/neu negative. While researching, two estrogen-pos-
itive cases (in pre-diagnosed MC of mammary gland) were attributed to invasive cancer with 
medullary component due to the presence of single glandular structures formed by cancer cells.
Fig. 2. Immunohistochemical study of MC and IDC.
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The status of tumors on receptor p53 and Ki-67 was as follows: p53+ status had 80%, 
85% of tumors had level of proliferative activity more than 10% (Ki-67 expression). With 
respect to receptor expression MMR1 and E-cadherin, the results were completely opposite. 
In 75% of cases MC cells expressed marker of adhesion in the thick solid line form and in 
100% of cases cells were receptor-negative for expression of MMP1. Regarding IDC (Fig. 2), 
results of immunohistochemical studies were different compared to MC of mammary gland 
(Table 1): the tumor cells are more expressed p53 (p <0.05), in the majority of cases ER, 
PR and MMP1 were present, E-cadherin expression was presented as fragments thin lines.
Table1. Differential criteria of diagnosis of medullary cancer and invasive ductal breast cancer.
Characteristics IDC МC
Consistency of tumor node Different, oftener dense Soft
Shape of the node Star-shaped, sometimes round Round
Boundaries of tumor Fuzzy Clear outlined
Secondary changes Often Rarely
The degree of cell differentiation Different, from low  to highly differentiated Low differentiated
Lymphoplasmacytic infiltration ± +
The presence of stroma ± –
The formation by cells of glands and ducts + –







Expression of HER2/neu 25% –
Expression of р53 20% 80%
Expression of Кі-67 75% 85%
Expression of Е-cadherin ± 75%
Expression of ММР1 60% –
Discussion
The low level of medullary cancer diagnosis is explained by the lack of clear histological 
and immunohistological criteria in diagnosis. Sometimes it is difficult to evaluate in practice 
such diagnostic features as state of verges [5]. Syncytial type of tumor cell growth, lack of 
tubular structures, lymphocytoplasmocytic infiltration, rarity (less than 25%) of necrosis in 
the tumor should be obvious and characteristic features of MC [6].
Note: “+” — indicates that the sign presents in the definite type of cancer, “–” — the sign is absent.
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Analyzing the opinion that MC is a form of IDC, and comparing with data obtained 
during the morphological, histological and immunohistochemical study, we can conclude 
that these two types of tumor are two different tumors. Tumor cells of MC have G2-G3 de-
gree of malignancy, and more often than other forms of cancer express p53, Ki-67, which 
are prognostically unfavorable-receptors and do not express prognostically favorable steroid 
hormone receptors [13, 14]. Instead, the known fact, this tumor has favorable behavior [6]. 
Exploring receptor E-cadherin, which is antimetastatic factor, we noted the possibility of 
expression this protein by MC cells.
Instead, the lack of receptors of MMP1 was found. They are used to measure the capacity 
to metastasize of breast cancer [12]. Combining the last two facts, it is clear, as prognosti-
cally unfavorable tumor has congenial passing with the absence of metastases in the nearest 
lymph nodes [11, 12].
Differential diagnostic criteria for two types of breast cancers are shown in Table 1, 
which includes macroscopical, morphological, histological and immunohistochemical char-
acteristics of the tumors.
Conclusions
The data of the study show that the invasive ductal carcinoma and medullary carcinoma 
are completely independent and different types of malignancy in the breast. The medullary 
cancer tissue has high degree of tumor tissue malignancy, higher levels of cell proliferative 
activity, the degree of p53 and E-cadherin expression and the lack of MMR1, ER and PR. 
The favorable behavior of medullary cancer is associated with expression of E-cadherin 
receptors, which are essentially adhesion factor and absence of MMP1 which are factors of 
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